3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide has been researched along with Mental Disorders in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Booij, J; de Haan, L; Lavalye, J; Linszen, D; van Amelsvoort, T | 1 |
| Klimke, A; Larisch, R | 1 |
2 other study(ies) available for 3-iodo-2-hydroxy-6-methoxy-n-((1-ethyl-2-pyrrolidinyl)methyl)benzamide and Mental Disorders
| Article | Year |
|---|---|
Subjective experiences during dopamine depletion.
Topics: Adult; alpha-Methyltyrosine; Benzamides; Corpus Striatum; Dopamine; Enzyme Inhibitors; Humans; Iodine Radioisotopes; Male; Mental Disorders; Pyrrolidines; Receptors, Dopamine D2; Research Design; Tomography, Emission-Computed, Single-Photon | 2005 |
[Clinical impact of cerebral dopamine-D2 receptor scintigraphy].
Topics: Benzamides; Brain; Carbon Radioisotopes; Fluorine Radioisotopes; Humans; Iodine Radioisotopes; Mental Disorders; Parkinson Disease; Pyrrolidines; Receptors, Dopamine D2; Schizophrenia; Substance-Related Disorders; Tissue Distribution; Tomography, Emission-Computed; Tomography, Emission-Computed, Single-Photon | 1998 |